• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌的侧别不能预测根治性前列腺切除术后前列腺特异性抗原复发情况。

Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.

作者信息

Mouraviev Vladimir, Sun Leon, Madden John F, Mayes Janice M, Moul Judd W, Polascik Thomas J

机构信息

Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

Urology. 2007 Dec;70(6):1141-5. doi: 10.1016/j.urology.2007.07.066.

DOI:10.1016/j.urology.2007.07.066
PMID:18158035
Abstract

OBJECTIVES

To evaluate biologic behaviors of unilateral cancers compared with bilateral cancers on prostate-specific antigen (PSA) recurrence after radical prostatectomy.

METHODS

Analysis included demographic, clinical, and pathologic parameters of 1184 men who underwent RP for clinically localized prostate cancer at our institution between 2002 and 2006. Final pathologic assessment was performed with particular attention to laterality and percentage of tumor involvement, along with other routine parameters. On the basis of percentage of tumor involvement, all cancer foci were ranked as 5% or less, 5.01% to 10%, 10.01% to 15%, or greater than 15%. Statistical analysis was performed with univariate and multivariate methods.

RESULTS

Overall, 19.2% of 1184 patients had completely unilateral cancers. Prostate-specific antigen recurrence was revealed in 164 of 1184 patients (13.9%) at a mean (+/- standard deviation) follow-up of 2.7 +/- 2.4 years. Among men who had recurrence, 26 of 227 (11.5%) had unilateral tumors and 138 of 957 (14.4%) had bilateral disease (P = 0.25). The most common characteristics associated with PSA recurrence of unilateral tumors in the Cox model were diagnostic PSA level, prostate weight, and pathologic Gleason score (P <0.05).

CONCLUSIONS

Unilateral or bilateral prostate cancer did not predict PSA recurrence in men receiving radical prostatectomy. In contrast, baseline PSA level and pathologic Gleason score strongly predicted PSA recurrence.

摘要

目的

评估根治性前列腺切除术后,单侧癌与双侧癌在前列腺特异性抗原(PSA)复发方面的生物学行为。

方法

分析了2002年至2006年间在本机构接受根治性前列腺切除术治疗临床局限性前列腺癌的1184名男性的人口统计学、临床和病理参数。进行最终病理评估时特别关注肿瘤的侧别和累及百分比,以及其他常规参数。根据肿瘤累及百分比,将所有癌灶分为5%及以下、5.01%至10%、10.01%至15%或大于15%。采用单因素和多因素方法进行统计分析。

结果

总体而言,1184例患者中有19.2%患有完全单侧癌。在平均随访时间为2.7±2.4年时,1184例患者中有164例(13.9%)出现前列腺特异性抗原复发。在复发的男性中,227例中有26例(11.5%)患有单侧肿瘤,957例中有138例(14.4%)患有双侧疾病(P = 0.25)。Cox模型中与单侧肿瘤PSA复发相关的最常见特征是诊断时的PSA水平、前列腺重量和病理Gleason评分(P <0.05)。

结论

单侧或双侧前列腺癌并不能预测接受根治性前列腺切除术男性的PSA复发。相比之下,基线PSA水平和病理Gleason评分能强烈预测PSA复发。

相似文献

1
Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.前列腺癌的侧别不能预测根治性前列腺切除术后前列腺特异性抗原复发情况。
Urology. 2007 Dec;70(6):1141-5. doi: 10.1016/j.urology.2007.07.066.
2
Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.前列腺癌核分级与根治性前列腺切除术后前列腺特异性抗原复发之间无相关性。
J Urol. 2001 Dec;166(6):2193-7.
3
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.前列腺穿刺活检癌灶在穿刺活检受累更严重一侧的百分比作为根治性前列腺切除术后前列腺特异性抗原复发的预测指标:来自共享平等准入区域癌症医院(SEARCH)数据库的结果
Cancer. 2003 Dec 1;98(11):2344-50. doi: 10.1002/cncr.11809.
4
Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.对于手术Gleason评分6分及以下的前列腺癌患者,肿瘤体积不能预测根治性前列腺切除术后的生化复发情况。
Urology. 2007 Aug;70(2):294-8. doi: 10.1016/j.urology.2007.03.062.
5
Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.根治性前列腺切除术治疗偶发性(T1a-T1b期)前列腺癌:残余疾病和生化复发的预测因素分析。
Eur Urol. 2008 Jul;54(1):118-25. doi: 10.1016/j.eururo.2008.02.018. Epub 2008 Feb 26.
6
Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.阳性活检核心的百分比、术前前列腺特异性抗原(PSA)水平、pT和Gleason评分作为根治性前列腺切除术后PSA复发的预测指标:日本一项多机构结局研究
BJU Int. 2006 Sep;98(3):549-53. doi: 10.1111/j.1464-410X.2006.06379.x.
7
Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.术前血清游离循环DNA在接受根治性前列腺切除术的前列腺癌男性患者中的预后价值。
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-7. doi: 10.1158/1078-0432.CCR-06-2781.
8
Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.使用磁共振成像综合变量、前列腺特异性抗原和 Gleason 评分的术前神经网络预测根治性前列腺切除术后前列腺癌生化复发情况。
Urology. 2004 Dec;64(6):1165-70. doi: 10.1016/j.urology.2004.06.030.
9
Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?在预测前列腺癌根治术后早期生化复发方面,前列腺特异性抗原(PSA)密度是否比术前PSA水平更具优势?
BJU Int. 2006 Mar;97(3):480-4. doi: 10.1111/j.1464-410X.2006.06022.x.
10
Preoperative PSA is still predictive of cancer volume and grade in late PSA era.在晚期前列腺特异抗原(PSA)时代,术前PSA仍可预测癌体积和分级。
Urology. 2007 Oct;70(4):711-6. doi: 10.1016/j.urology.2007.06.640.

引用本文的文献

1
Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy.根治性前列腺切除术标本中最大肿瘤和次要肿瘤的组织学特征及其对局灶性治疗的意义。
Diagn Pathol. 2019 Jan 12;14(1):2. doi: 10.1186/s13000-019-0782-8.
2
Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.肿瘤累及百分比与低危前列腺癌 Gleason 评分升级的相关性。
Med Oncol. 2012 Dec;29(5):3339-44. doi: 10.1007/s12032-012-0270-4. Epub 2012 Jun 12.
3
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
基于前列腺特异性抗原筛查的局限性前列腺癌行局部治疗的适宜性:来自 ProtecT 研究的经验。
Br J Cancer. 2011 Sep 27;105(7):931-7. doi: 10.1038/bjc.2011.314. Epub 2011 Aug 23.
4
Tumor focality in prostate cancer: implications for focal therapy.前列腺癌的肿瘤局灶性:对局部治疗的影响。
Nat Rev Clin Oncol. 2011 Jan;8(1):48-55. doi: 10.1038/nrclinonc.2010.190. Epub 2010 Nov 23.
5
Proton radiation for localized prostate cancer.局部前列腺癌的质子放射治疗。
Nat Rev Urol. 2009 Jun;6(6):324-30. doi: 10.1038/nrurol.2009.83. Epub 2009 May 12.
6
Pathologic basis of focal therapy for early-stage prostate cancer.早期前列腺癌局部治疗的病理学基础。
Nat Rev Urol. 2009 Apr;6(4):205-15. doi: 10.1038/nrurol.2009.29.